Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
NCT06631287 · Long COVID, Sars-CoV-2 Infection, Coronavirus Infections
The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures, in participants with Long COVID.
PhasePhase 3
TypeInterventional
Age18 Years
WhereTucson, Arizona, United States + 15 more
SponsorWes Ely
▾Tap for detailsClick for full details — eligibility, all locations, contacts
16 sitesApply